Regeneron gets CRL as it shoots for approval of Eylea in diabetic eye disease
admin 25th October 2018 Uncategorised 0Regeneron’s top-selling blockbuster Eylea has shown good results for a new, and potentially lucrative, indication, hitting its one-year endpoints in a phase 3 trial. Its prefilled syringe, however, did not.
More: Regeneron gets CRL as it shoots for approval of Eylea in diabetic eye disease
Source: fierce